366017-09-6 Mubritinib AKSci X7505
 
 
Loading Please Wait...
  X7505    
Mubritinib
, 98%
 
TAK-165




IDENTITY
CAS Number:366017-09-6
MDL Number:MFCD09954135
MF:C25H23F3N4O2
MW:468.47
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:98%
Physical Form (at 20°C):Solid
Melting Point:158-162’C
Long-Term Storage:Store long-term at 2-8°C
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

BIOLOGICAL INFO
Solubility:DMSO
Application(s):EGFR, CDK
Form:Free Base
Research Area:Cancer

REVIEW

 Mubritinib (TAK-165) is a HER2/ErbB2 protein kinase inhibitor with IC50 of 6 nM; no activity to EGFR, FGFR, PDGFR, JAK1, Src and Blk. The compound was under development by Takeda for the treatment of cancer. Mubritinib reduced HER2/Neu-enhanced phosphorylated AR and MAP kinase, indicating that the MAP kinase pathway seems to be involved in the phosphorylation of the AR by HER2/Neu. Both HER2/Neu inhibitor Mubritinib successfully reduced the HER2/Neu-induced transactivation activity of the AR in PC-3 and DU-145 cells, suggesting that such an inhibitor was a possible therapeutic drug for patients with hormone-refractory prostate cancer. Mubritinib completed phase I clinical trials but appears to have been discontinued, as no new information on the drug has surfaced since December 2008.

REFERENCES
[1]Tasaka, Akihiro; Hitaka, Takenori; Matsutani, Etsuya Preparation of 2-styryl-4-(phenoxymethyl)oxazole derivatives as tyrosine kinase inhibitors, PCT Int. Appl. (2001), WO 2001077107 A1 20011018.
[2] Sugita, Shozo; Kawashima, Hidenori; Tanaka, Tomoaki; Kurisu, Takeshi; Sugimura, Kazunobu; Nakatani, Tatsuya Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor, Oncology Reports (2004), 11(6), 1273-1279.
[3] Nagasawa, Joji; Mizokami, Atsushi; Koshida, Kiyoshi; Yoshida, Sei; Naito, Kenichiro; Namiki, Mikio Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo International Journal of Urology (2006), 13(5), 587-592.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


Current as of April 30, 2024


Download SDS Request COA

All products are stocked and shipped from San Francisco Bay Area, California, USA.

⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.



CATEGORIES

 APIs and Bioactives >


PubChem
  @PubMed